DUSA Pharmaceuticals Announces Exclusive Agreement With Daewoong Pharmaceutical Co., Ltd. To Market DUSA's Levulan'R' Kerastick'R' For Photodynamic Therapy In Asian Territories

WILMINGTON, MASSACHUSETTS -- (MARKET WIRE) -- January 08, 2007 -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), announced today that it has entered into an exclusive marketing, distribution and supply agreement for certain Asian territories with Daewoong Pharmaceutical Co., Ltd., a market leader in prescription drugs in the region for dermatology. The agreement covers current and future uses of DUSA's proprietary Levulan® Kerastick® for photodynamic therapy (PDT) in dermatology.

Back to news